{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T18:57:46Z","timestamp":1787338666052,"version":"build-2736575974"},"reference-count":186,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.acvd.2021.10.009","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T14:06:11Z","timestamp":1637849171000},"page":"828-847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Soci\u00e9t\u00e9 Francophone d\u2019Ath\u00e9roscl\u00e9rose (NSFA)"],"prefix":"10.1016","volume":"114","author":[{"given":"Vincent","family":"Durlach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bonnefont-Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Boccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9261-1551","authenticated-orcid":false,"given":"Mathilde","family":"Varret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-5908","authenticated-orcid":false,"given":"Mathilde","family":"Di-Filippo Charcosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybil","family":"Charriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-722X","authenticated-orcid":false,"given":"Pierre E.","family":"Morange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Meilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-9084","authenticated-orcid":false,"given":"Gilles","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1100-8759","authenticated-orcid":false,"given":"Philippe","family":"Gillery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Beliard-Lasserre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Carri\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Ferri\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. John","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-3975","authenticated-orcid":false,"given":"Eduardo","family":"Angl\u00e9s-Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2021.10.009_bib0935","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in Man\u00a0\u2013\u00a0the Lp System","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"10.1016\/j.acvd.2021.10.009_bib0940","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1073\/pnas.84.10.3224","article-title":"Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen","volume":"84","author":"Eaton","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.acvd.2021.10.009_bib0945","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.acvd.2021.10.009_bib0950","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.acvd.2021.10.009_bib0955","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian Randomization Analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib0960","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/cvr\/cvab060","article-title":"Apolipoprotein B is an insufficient explanation for the risk of coronary disease associated with lipoprotein(a)","volume":"117","author":"Trinder","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib0965","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib0970","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0003319716637792","article-title":"Lipoprotein(a) levels in patients with abdominal aortic aneurysm","volume":"68","author":"Kotani","year":"2017","journal-title":"Angiology"},{"key":"10.1016\/j.acvd.2021.10.009_bib0975","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11789-019-00093-5","article-title":"Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region","volume":"14","author":"Kronenberg","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.acvd.2021.10.009_bib0980","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1161\/ATVBAHA.115.305306","article-title":"Heritability of biomarkers of oxidized lipoproteins: twin pair study","volume":"35","author":"Rao","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib0985","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/oxfordjournals.aje.a116517","article-title":"Serum lipoprotein(a) levels in racially different populations","volume":"136","author":"Cobbaert","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib0990","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Pare","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.009_bib0995","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/360670a0","article-title":"Atherogenesis in transgenic mice expressing human apolipoprotein(a)","volume":"360","author":"Lawn","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.acvd.2021.10.009_bib1000","doi-asserted-by":"crossref","first-page":"11584","DOI":"10.1073\/pnas.89.23.11584","article-title":"Characterization by yeast artificial chromosome cloning of the linked apolipoprotein(a) and plasminogen genes and identification of the apolipoprotein(a) 5\u2032 flanking region","volume":"89","author":"Malgaretti","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.acvd.2021.10.009_bib1005","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/hmg\/3.3.437","article-title":"Molecular characterisation of the human apo(a)-plasminogen gene family clustered on the telomeric region of chromosome 6 (6q26-27)","volume":"3","author":"Magnaghi","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/prot.340120212","article-title":"A structural assessment of the apo[a] protein of human lipoprotein[a]","volume":"12","author":"Guevara","year":"1992","journal-title":"Proteins"},{"issue":"Suppl. 1","key":"10.1016\/j.acvd.2021.10.009_bib1015","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1111\/jth.12935","article-title":"Basic mechanisms and regulation of fibrinolysis","volume":"13","author":"Longstaff","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2021.10.009_bib1020","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1538-7836.2012.04765.x","article-title":"Crystal structure of the native plasminogen reveals an activation-resistant compact conformation","volume":"10","author":"Xue","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2021.10.009_bib1025","doi-asserted-by":"crossref","first-page":"7630","DOI":"10.1021\/bi00244a035","article-title":"Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines","volume":"30","author":"Fleury","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.acvd.2021.10.009_bib1030","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1161\/01.ATV.13.5.758","article-title":"Comparison of ligand-binding sites of modeled apo[a] kringle-like sequences in human lipoprotein[a]","volume":"13","author":"Guevara","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.acvd.2021.10.009_bib1035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.acvd.2021.10.009_bib1040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0378-1119(97)00657-4","article-title":"The number of kringle IV repeats 3\u201310 is invariable in the human apo(a) gene","volume":"208","author":"Haibach","year":"1998","journal-title":"Gene"},{"key":"10.1016\/j.acvd.2021.10.009_bib1045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0167-4838(99)00179-X","article-title":"Effect of plasminogen activators on human recombinant apolipoprotein(a) having the plasminogen activation cleavage site","volume":"1434","author":"Hervio","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.acvd.2021.10.009_bib1050","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1172\/JCI113093","article-title":"Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma","volume":"80","author":"Utermann","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.acvd.2021.10.009_bib1055","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/01.ATV.0000144010.55563.63","article-title":"Lipoprotein(a): an elusive cardiovascular risk factor","volume":"24","author":"Berglund","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1060","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/01.CIR.0000048125.79640.77","article-title":"Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction","volume":"107","author":"Holmer","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.009_bib1065","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI117126","article-title":"Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles","volume":"93","author":"Perombelon","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.acvd.2021.10.009_bib1070","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1075","article-title":"Cis-epistasis at the LPA locus and risk of cardiovascular disease","author":"Zeng","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0021-9150(02)00315-5","article-title":"Sequence and functional changes in a putative enhancer region upstream of the apolipoprotein(a) gene","volume":"166","author":"Puckey","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2021.10.009_bib1085","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1172\/JCI118015","article-title":"A pentanucleotide repeat polymorphism in the 5\u2032 control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians","volume":"96","author":"Trommsdorff","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.acvd.2021.10.009_bib1090","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0022-2275(20)41491-9","article-title":"Ten allelic apolipoprotein[a] 5\u2032 flanking fragments exhibit comparable promoter activities in HepG2 cells","volume":"36","author":"Bopp","year":"1995","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1095","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/jmg.2006.042119","article-title":"Three single nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans","volume":"43","author":"Chretien","year":"2006","journal-title":"J Med Genet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0021-9150(96)05993-X","article-title":"Characterization of the genetic elements controlling lipoprotein(a) concentrations in Mexican Americans. Evidence for at least three controlling elements linked to LPA, the locus encoding apolipoprotein(a)","volume":"128","author":"Rainwater","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2021.10.009_bib1105","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1110","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1093\/hmg\/ddu731","article-title":"Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels","volume":"24","author":"Lu","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1115","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/hmg\/10.8.815","article-title":"Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians","volume":"10","author":"Ogorelkova","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF00225193","article-title":"Sequence polymorphism in kringle IV 37 in linkage disequilibrium with the apolipoprotein (a) size polymorphism","volume":"95","author":"Kraft","year":"1995","journal-title":"Hum Genet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/hmg\/7.2.257","article-title":"Significant impact of the +93C\/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium","volume":"7","author":"Kraft","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1130","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/hmg\/8.11.2087","article-title":"Molecular basis of congenital lp(a) deficiency: a frequent apo(a) \u2018null\u2019 mutation in caucasians","volume":"8","author":"Ogorelkova","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/humu.20101","article-title":"A common nonsense mutation in the repetitive Kringle IV-2 domain of human apolipoprotein(a) results in a truncated protein and low plasma Lp(a)","volume":"24","author":"Parson","year":"2004","journal-title":"Hum Mutat"},{"key":"10.1016\/j.acvd.2021.10.009_bib1140","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1194\/jlr.M094540","article-title":"Non-synonymous SNPs in LPA homologous to plasminogen deficiency mutants represent novel null apo(a) alleles","volume":"61","author":"Morgan","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1145","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1038\/s41467-018-04668-w","article-title":"Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries","volume":"9","author":"Zekavat","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.acvd.2021.10.009_bib1150","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein(a) in Alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: Mendelian randomization investigation","volume":"141","author":"Larsson","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.acvd.2021.10.009_bib1155","first-page":"1","article-title":"Clinical utility of lipoprotein(a) and LPA Genetic Risk Score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1042\/CS20160403","article-title":"The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies","volume":"131","author":"Lambert","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.acvd.2021.10.009_bib1165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1170","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1175","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"Pt 1","key":"10.1016\/j.acvd.2021.10.009_bib1180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/000456329603300110","article-title":"A comparative study of six commercial lipoprotein(a) assays in seventeen laboratories within the British Isles","volume":"33","author":"Mackness","year":"1996","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.acvd.2021.10.009_bib1185","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/clinchem\/hvaa054","article-title":"Analytical performance specifications for lipoprotein(a), apolipoprotein B-100, and apolipoprotein A-I using the biological variation model in the EuBIVAS population","volume":"66","author":"Clouet-Foraison","year":"2020","journal-title":"Clin Chem"},{"key":"10.1016\/j.acvd.2021.10.009_bib1190","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1195","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1200","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.acvd.2021.10.009_bib1205","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.acvd.2021.10.009_bib1210","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.acvd.2021.10.009_bib1215","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2021.10.009_bib1220","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2020.05.002","article-title":"Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: an Italian case-control multicenter study on Lp(a)","volume":"14","author":"Stefanutti","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1230","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cca.2020.10.010","article-title":"Quantifying apolipoprotein(a) in the era of proteoforms and precision medicine","volume":"511","author":"Ruhaak","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.acvd.2021.10.009_bib1235","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.acvd.2021.10.009_bib1240","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/clinchem\/hvaa239","article-title":"Towards an SI-traceable reference measurement system for seven serum apolipoproteins using bottom-up quantitative proteomics: conceptual approach enabled by cross-disciplinary\/cross-sector collaboration","volume":"67","author":"Cobbaert","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.acvd.2021.10.009_bib1245","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1250","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"\u2018LDL-C\u2019 = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1255","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2019.12.005","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"294","author":"Nordestgaard","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2021.10.009_bib1260","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.jlr.2021.100053","article-title":"Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements","volume":"62","author":"Yeang","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1265","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1270","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/qjmed\/93.2.75","article-title":"Lipoprotein(a): from ancestral benefit to modern pathogen?","volume":"93","author":"Lippi","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.acvd.2021.10.009_bib1275","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/01.ATV.16.4.523","article-title":"Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of \u2018degenerative\u2019 valvular aortic stenosis","volume":"16","author":"O\u2019Brien","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1280","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.009_bib1285","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","article-title":"Lipoprotein(a): the revenant","volume":"38","author":"Gencer","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.10.009_bib1290","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1295","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/eurheartj\/ehx233","article-title":"Lipoprotein(a)","volume":"38","author":"Eckardstein","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.10.009_bib1300","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1305","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1310","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/ATVBAHA.120.314287","article-title":"Human aortic valve interstitial cells display proangiogenic properties during calcific aortic valve disease","volume":"41","author":"Gendron","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1315","doi-asserted-by":"crossref","first-page":"13353","DOI":"10.1021\/bi00041a011","article-title":"Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis","volume":"34","author":"Hervio","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.acvd.2021.10.009_bib1320","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/01.ATV.20.2.575","article-title":"Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: an in vitro study using plasma from children with idiopathic nephrotic syndrome","volume":"20","author":"Soulat","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1325","doi-asserted-by":"crossref","first-page":"141806","DOI":"10.1155\/2012\/141806","article-title":"So many plasminogen receptors: why?","volume":"2012","author":"Plow","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1330","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1021\/bi00068a021","article-title":"Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation","volume":"32","author":"Ezratty","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.acvd.2021.10.009_bib1335","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2362.1996.156288.x","article-title":"The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin","volume":"26","author":"Hervio","year":"1996","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.acvd.2021.10.009_bib1340","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1021\/bi00142a024","article-title":"Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments","volume":"31","author":"Rouy","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.acvd.2021.10.009_bib1345","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0037-1615654","article-title":"Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation","volume":"85","author":"Martinez","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.acvd.2021.10.009_bib1350","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/01.ATV.0000021144.87870.C8","article-title":"Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody","volume":"22","author":"Kang","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1355","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood.V82.2.392.392","article-title":"Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?","volume":"82","author":"Hervio","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.acvd.2021.10.009_bib1360","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1365","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1194\/jlr.P094763","article-title":"Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis","volume":"60","author":"Boffa","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1370","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1016\/S0021-9258(18)89264-X","article-title":"Binding and activation of plasminogen on the platelet surface","volume":"260","author":"Miles","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1016\/j.acvd.2021.10.009_bib1375","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.ATV.11.3.629","article-title":"Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu","volume":"11","author":"Rouy","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.acvd.2021.10.009_bib1380","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1194\/jlr.M036566","article-title":"Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)","volume":"55","author":"Romagnuolo","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1385","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1074\/jbc.RA119.011251","article-title":"Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function","volume":"295","author":"Sandmark","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.acvd.2021.10.009_bib1390","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/01.ATV.18.9.1393","article-title":"Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN","volume":"18","author":"Rand","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1395","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.jacc.2003.08.066","article-title":"High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort","volume":"43","author":"Wu","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1400","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1016\/S0021-9258(18)52266-3","article-title":"Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis","volume":"266","author":"Etingin","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.acvd.2021.10.009_bib1405","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archinte.168.6.598","article-title":"Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data","volume":"168","author":"Bennet","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1410","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.10.009_bib1415","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors C.","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2021.10.009_bib1420","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng.2480","article-title":"Large-scale association analysis identifies new risk loci for coronary artery disease","volume":"45","author":"CARDIoGRAMplusC4D Consortium","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1425","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11789-019-00101-8","article-title":"Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism?","volume":"14","author":"Nave","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.acvd.2021.10.009_bib1430","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1161\/STROKEAHA.106.480657","article-title":"Lipoprotein (a) and stroke: a meta-analysis of observational studies","volume":"38","author":"Smolders","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.acvd.2021.10.009_bib1435","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants","volume":"55","author":"Erqou","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1440","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis","volume":"242","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2021.10.009_bib1445","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/ATVBAHA.118.311857","article-title":"Lipoprotein(a) and risk of ischemic stroke in the REGARDS Study","volume":"39","author":"Arora","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1450","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1455","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1460","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/01.CIR.100.7.743","article-title":"Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood","volume":"100","author":"Nowak-Gottl","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.009_bib1465","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1046\/j.1538-7836.2003.00158.x","article-title":"Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease","volume":"1","author":"Revel-Vilk","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2021.10.009_bib1470","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvu107","article-title":"Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts","volume":"103","author":"Laschkolnig","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1475","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/CIRCULATIONAHA.121.053797","article-title":"Prioritizing the role of major lipoproteins and subfractions as risk factors for peripheral artery disease","volume":"144","author":"Levin","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.009_bib1480","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2020.11.025","article-title":"Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: the CAVASIC study","volume":"316","author":"Kheirkhah","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2021.10.009_bib1485","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2018.02.007","article-title":"Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease","volume":"12","author":"Verweij","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1490","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjcard.2020.11.014","article-title":"Aspirin in primary prevention: what changed? A critical appraisal of current evidence","volume":"141","author":"Dasa","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1495","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.acvd.2021.10.009_bib1500","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1505","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1510","first-page":"709","volume":"5","author":"Bergmark","year":"2020","journal-title":"An exploratory analysis of proprotein convertase subtilisin\/kexin type 9 inhibition and aortic stenosis in the FOURIER Trial. JAMA Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1515","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/ehjci\/jev338","article-title":"Lipoprotein(a) is a risk factor for aortic and mitral valvular stenosis in peripheral arterial disease","volume":"17","author":"Hojo","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.acvd.2021.10.009_bib1520","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.009_bib1525","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1530","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.lpm.2013.01.053","article-title":"[Diagnostic and treatment of familial hypercholesterolemia (FH) in adult: guidelines from the New French Society of Atherosclerosis (NSFA)]","volume":"42","author":"Farnier","year":"2013","journal-title":"Presse Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1535","doi-asserted-by":"crossref","first-page":"3478a","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.10.009_bib1540","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1545","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1253\/circj.CJ-15-0999","article-title":"Lipoprotein(a) in familial hypercholesterolemia with proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutations","volume":"80","author":"Tada","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.acvd.2021.10.009_bib1550","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","article-title":"Lipoprotein(a) in homozygous familial hypercholesterolemia","volume":"20","author":"Kraft","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1555","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2213-8587(16)30147-4","article-title":"Lipoprotein(a) and familial hypercholesterolaemia\u00a0\u2013\u00a0Authors\u2019 reply","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1560","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.jacc.2020.03.065","article-title":"Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia","volume":"75","author":"Trinder","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1565","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.cca.2011.05.036","article-title":"Lipoprotein(a)-cholesterol: a significant component of serum cholesterol","volume":"412","author":"Kinpara","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.acvd.2021.10.009_bib1570","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1575","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/joim.12981","article-title":"Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities","volume":"287","author":"Vuorio","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1580","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.009_bib1585","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2021.10.009_bib1590","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.10.009_bib1595","doi-asserted-by":"crossref","first-page":"108622","DOI":"10.1016\/j.diabres.2020.108622","article-title":"The association between lipoprotein (a) and carotid atherosclerosis in patients with type 2 diabetes without pre-existing cardiovascular disease: a cross-sectional study","volume":"171","author":"Jun","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.acvd.2021.10.009_bib1600","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2018.12.022","article-title":"Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the Atherosclerosis Risk in Communities study","volume":"282","author":"Saeed","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2021.10.009_bib1605","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2337\/dc19-0274","article-title":"Lipoprotein(a) and cardiovascular outcomes in patients with coronary artery disease and prediabetes or diabetes","volume":"42","author":"Jin","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2021.10.009_bib1610","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","article-title":"Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature","volume":"16","author":"Paige","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1615","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1620","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2337\/dc20-2842","article-title":"Relation of lipoprotein(a) levels to incident type 2 diabetes and modification by alirocumab treatment","volume":"44","author":"Schwartz","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2021.10.009_bib1625","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2337\/dc19-1398","article-title":"The association of lipoprotein(a) plasma levels with prevalence of cardiovascular disease and metabolic control status in patients with type 1 diabetes","volume":"43","author":"Littmann","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.acvd.2021.10.009_bib1630","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1055\/s-0036-1598002","article-title":"Lipoprotein(a) as a risk factor for venous thromboembolism: a systematic review and meta-analysis of the literature","volume":"43","author":"Dentali","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.acvd.2021.10.009_bib1635","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.amjmed.2003.06.005","article-title":"Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism","volume":"115","author":"Marcucci","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1640","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.wneu.2015.10.059","article-title":"An increased serum level of lipoprotein(a) is a predictor for deep vein thrombosis in patients with spinal cord injuries","volume":"87","author":"Wang","year":"2016","journal-title":"World Neurosurg"},{"key":"10.1016\/j.acvd.2021.10.009_bib1645","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620912020","article-title":"Serum lipoprotein (a) on postoperative day 3: a strong predictor of portal and\/or splenic vein thrombosis in cirrhotic patients with splenectomy","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.acvd.2021.10.009_bib1650","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1655","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.009_bib1660","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1665","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism","volume":"60","author":"Helgadottir","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1670","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1675","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC Study (Chronic Renal Insufficiency Cohort)","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1680","first-page":"287","article-title":"[Relationship between blood fibrinogen and plasma lipoproteins in patients with hypercholesterolemia]","volume":"85","author":"Alessandri","year":"1994","journal-title":"Minerva Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1685","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0753-3322(96)82666-7","article-title":"Lipoprotein (a) and fibrinolytic system in liver cirrhosis. Coagulation Abnormalities in Liver Cirrhosis (CALC) Study Group","volume":"49","author":"Cimminiello","year":"1995","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.acvd.2021.10.009_bib1690","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1695","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.009_bib1700","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1705","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.10.009_bib1710","doi-asserted-by":"crossref","first-page":"44B","DOI":"10.1016\/j.amjcard.2008.02.031","article-title":"Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations","volume":"101","author":"Scanu","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1715","doi-asserted-by":"crossref","first-page":"e001696","DOI":"10.1161\/CIRCGEN.117.001696","article-title":"Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE Study","volume":"11","author":"Parish","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1720","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1725","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1730","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (Cholesteryl Ester Transfer Protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1735","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2021.10.009_bib1740","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"HPS3\/TIMI55 Collaborative Group","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1745","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1750","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1755","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","author":"Merki","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.009_bib1760","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1194\/jlr.P082834","article-title":"Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects","volume":"59","author":"Nandakumar","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1765","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1770","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1775","doi-asserted-by":"crossref","first-page":"e0180869","DOI":"10.1371\/journal.pone.0180869","article-title":"Roles of the low-density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin\/kexin type 9","volume":"12","author":"Romagnuolo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.acvd.2021.10.009_bib1780","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.acvd.2021.10.009_bib1785","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1042\/CS20180040","article-title":"PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate","volume":"132","author":"Croyal","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.acvd.2021.10.009_bib1790","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2021.10.009_bib1795","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.10.009_bib1800","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jacbts.2020.03.008","article-title":"Lipoprotein(a) cellular uptake ex vivo and hepatic capture in vivo is insensitive to PCSK9 inhibition with alirocumab","volume":"5","author":"Chemello","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"8","key":"10.1016\/j.acvd.2021.10.009_bib1805","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/2047487320915803","article-title":"Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: a pooled analysis from 10 ODYSSEY Phase 3 studies","volume":"28","author":"Mahmood","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1810","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1815","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL-cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1820","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MOL.0000000000000549","article-title":"RNA-targeted therapeutics for lipid disorders","volume":"29","author":"Tsimikas","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1825","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1830","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2021.10.009_bib1835","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1840","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2021.10.009_bib1845","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.atherosclerosissup.2017.05.006","article-title":"Current insights into the German Lipoprotein Apheresis Registry (GLAR)\u00a0\u2013\u00a0Almost 5 years on","volume":"30","author":"Schettler","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.acvd.2021.10.009_bib1850","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.acvd.2021.10.009_bib1855","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2021.10.009_bib1860","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213621001868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213621001868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:47:43Z","timestamp":1761745663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213621001868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":186,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1875213621001868"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2021.10.009","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Soci\u00e9t\u00e9 Francophone d\u2019Ath\u00e9roscl\u00e9rose (NSFA)","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2021.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}